Improved long-term prognosis after myocardial infarction 1984-1991.

AIMS We set out to examine whether long term prognosis in terms of 2-year mortality after myocardial infarction has improved after the introduction of intravenous beta-blockers, nitroglycerin infusion, aspirin and thrombolytics, in an unselected population of patients hospitalized with a myocardial infarction. METHODS AND RESULTS We investigated retrospectively 3791 acute myocardial infarctions in 3187 Göteborg women and men (1039 women and 2148 men), who were consecutively admitted to the coronary care unit at the Ostra hospital during 1984-1991. Throughout this period, data were entered continuously into the coronary care unit database. Mortality data were collected through the Swedish cause-specific mortality register. The primary end-point was mortality within 2 years after the onset of the index infarction. Two-year mortality decreased from 36% in 1984 to 25% in 1991. In a Cox regression model (including myocardial infarctions up to 1993) year of hospitalization, age, diabetes mellitus, sex, prior myocardial infarction and indeterminable infarct location all had a significant impact on survival after myocardial infarct. Thrombolytic therapy and hypertension had no prognostic significance. CONCLUSION Against a background of radical changes in the treatment of acute myocardial infarction during 1984-1991 we have seen decreasing in-hospital mortality as well as a substantial decrease in 2-year mortality.

[1]  A. Folsom,et al.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. , 1996, The New England journal of medicine.

[2]  M. Gheorghiade,et al.  Decline in the rate of hospital mortality from acute myocardial infarction: impact of changing management strategies. , 1996, American heart journal.

[3]  C D Naylor,et al.  Population-wide mortality trends among patients hospitalized for acute myocardial infarction: the Ontario experience, 1981 to 1991. , 1994, Journal of the American College of Cardiology.

[4]  L. Parsons,et al.  Acute myocardial infarction in women: survival analysis in first six months , 1994, BMJ.

[5]  R. Gillum,et al.  Trends in acute myocardial infarction and coronary heart disease death in the United States. , 1994, Journal of the American College of Cardiology.

[6]  J. Murabito,et al.  Prognosis After the Onset of Coronary Heart Disease An Investigation of Differences in Outcome Between the Sexes According to Initial Coronary Disease Presentation , 1993, Circulation.

[7]  K. Lee,et al.  Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. , 1993, Journal of the American College of Cardiology.

[8]  J. Herlitz,et al.  Predictors of death and ventricular fibrillation in acute myocardial infarction , 1992 .

[9]  P. Greenland,et al.  In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. , 1991, Circulation.

[10]  A. Skene,et al.  Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study , 1990, The Lancet.

[11]  W. Dassen,et al.  Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. , 1990, Journal of the American College of Cardiology.

[12]  M Gent,et al.  Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. , 1989, Journal of the American College of Cardiology.

[13]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[14]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[15]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[16]  E. Gilpin,et al.  Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. , 1988, The American journal of cardiology.

[17]  R. Conroy,et al.  Risk factors and in-hospital course of first episode of myocardial infarction or acute coronary insufficiency in women. , 1988, Journal of the American College of Cardiology.

[18]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico. LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[19]  C. Furberg Secondary prevention trials after acute myocardial infarction. , 1987, The American journal of cardiology.

[20]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .

[21]  S. Willich,et al.  Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. , 1987, Journal of the American College of Cardiology.

[22]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[23]  L. Køber,et al.  Improving long-term survival of patients with acute myocardial infarction from 1977-1988 in a region of Denmark. , 1995, European heart journal.

[24]  K. Swedberg,et al.  Declining hospital mortality in acute myocardial infarction. , 1994, European heart journal.

[25]  C. Furberg Secondary Prevention Trials After Myocardial Infarction , 1988, Journal of cardiovascular pharmacology.